BioSpace News Archive

Inari Medical, Inc. announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients with chronic limb-threatening ischemia.

Today, the U.S. Food and Drug Administration granted marketing authorization to LetsGetChecked for the Simple 2 Test.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Propella Therapeutics, Inc. (President and CEO: William Moore, “Propella”) today announced that Astellas, through a U.S. subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will acquire Propella.

Kyverna Therapeutics, Inc. (Kyverna) today announced the publication in The Lancet Neurology of a Letter to the Editor by a group of German investigators describing the first case of treatment using KYV-101 in a 33 year-old patient with severe, treatment-refractory, anti-acetylcholine receptor auto-antibody positive, generalized myasthenia gravis (MG), who was treated on a named patient basis outside of a clinical trial setting.

LetsGetChecked, a global healthcare solutions company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo classification request for its Simple 2 at-home collection system.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to XPHOZAH® (tenapanor) for the treatment of pediatric hyperphosphatemia.

Regeneron Pharmaceuticals, Inc. will webcast management participation.

Agilent Technologies Inc. announced the company has increased its quarterly dividend to 23.6 cents per share of common stock, a 5% increase over the previous dividend.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manuscript titled “LAIR-1 Agonism as a Therapy for Acute Myeloid Leukemia” in the Journal of Clinical Investigation.

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in a fireside discussion and one-on-one meetings at the Piper Sandler Healthcare Conference being held November 28-30, 2023 in New York City.